Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

In its weekly update today, the US Centers for Disease Control and Prevention (CDC) reported 40 more measles cases today, ...

Relative to before the pandemic, the number of vaccinated participants fell 10% among children and 4% in adults in pandemic ...

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...